On June 10, 2015, the fifth subject was enrolled in our ongoing Canadian study of MDMA-assisted psychotherapy for PTSD. Led by Principal Investigator Ingrid Pacey, M.D., in Vancouver, B.C., this Phase 2 study will treat up to 12 subjects with chronic, treatment-resistant PTSD from sexual assault, violent crime, military service, or any other cause. “Two subjects have completed treatment and two subjects are partially through their crossover treatments, with some of them experiencing clinically significant improvements,” reports MAPS Clinical Research Scientist Berra Yazar-Klosinski, Ph.D. “The last two subjects are due to start their experimental sessions in the next two weeks. We are hopeful to have these last subjects complete through the primary endpoint by September 2015.” MAPS Canada
